Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

CNS Pharmaceuticals Q2 2024 Net Loss Reduced To $2.5M Due To Lower CRO Expenses; R&D Costs Decrease To $1.1M; G&A Expenses Increase To $1.4M Due To Higher Legal And Professional Fees

Author: Benzinga Newsdesk | August 15, 2024 08:18am

Cash Position At $1.5M With Additional $12.4M Raised Post-June 30; Sufficient Funds Through Q1 2025, Final Berubicin Trial Data Expected H1 2025

Posted In: CNSP